The regulation of clinical trials in the Republic of Serbia

• Main Authors: Vučinić Zorica M. (Author), Đukić Ljiljana C. (Author)
• Format: Book
• Published: Srpsko lekarsko drustvo, 2015-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2334-9492; 2334-9492; 10.5937/hpimj1503322V
• Keywords: clinical trials; regulation; EU directive; ALIMS; Therapeutics. Pharmacology; RM1-950
• Source: Hospital Pharmacology, Vol 2, Iss 3, Pp 322-327 (2015)

Introduction: Modern trends in drug production and traffic of drugs as a primary marketing resource of high quality efficient and safe drugs have an important task to provide safe, effective and quality medicines through clinical trials. Topic: Overview of current regulations established in the field of clinical trials of drugs and the importance of carrying out clinical trials is pointed herein. Methods: Pursuant to the applicable regulations in the Republic of Serbia and those established at the level of the European Agency (EMA) is provided an overview of the key elements essential for the objective procedures carried out in clinical trials of drugs in Serbia. Conclusion: Modern drug therapy today is exposed to serious challenges given the numerous studies in the field of medicine and pharmacy carried out in the world today. Clinical trials are particularly vulnerable segment in this area and require the participants in these processes to be highly educated and to have the serious ethical approach to all stages of the process.